Phase I dose-escalation study of oral SKI-606 [bosutinib] in subjects with advanced malignant solid tumors

Trial Profile

Phase I dose-escalation study of oral SKI-606 [bosutinib] in subjects with advanced malignant solid tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Feb 2013

At a glance

  • Drugs Bosutinib (Primary)
  • Indications Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 21 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Nov 2009 Planned end date changed from 1 Jun 2008 to 1 Dec 2009 as reported by ClinicalTrials.gov.
    • 03 Nov 2009 Planned number of patients changed from 150 to 151 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top